The STOPFOP team is pleased to announce that the "Saracatinib Trial to Prevent Fibrodysplasia Ossificans Progressiva" (STOPFOP) has restarted recruitment for the Amsterdam study site and participants are currently enrolled or being enrolled. The study sites in Garmish-Partenkirchen and London are expecting to start inclusions shortly.

Due to the COVID-19 pandemic the start of the study had to be paused because hospitals were being fully dedicated to fighting the outbreak. Now, with additional precautions, the study can once again help move research into FOP drugs forward.

“We have put measures into place to make sure that visits to our centers will be conducted in a clean and safe environment," says Dr. Marelise Eekhoff, coordinating investigator for the trial. The STOPFOP team remains dedicated to the discovery of effective drugs to treat FOP. Dr. Bernard Smilde, associate investigator, comments: “Anyone who wishes to learn more about the study or to contact the researchers can do so through our website.”

Patients or caregivers who wish to learn more about this trial, or to contact the researchers, can find more information on the website www.stopfop.com.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 821600. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.